Ozanimod (Zeposia) accepted for restricted use within NHS Scotland for treatment of relapsing remitting multiple sclerosis

Treatment is restricted to adult patients with relapsing remitting multiple sclerosis, with active disease as defined by clinical or imaging features, who are requesting an oral treatment.

Source:

Scottish Medicines Consortium